Pfizer’s COVID Pill Paxlovid Shows No Benefit In Younger Adults: Study
Paxlovid was approved by the FDA late last year for people and children 12 and older who are classified high risk. However, Pfizer’s COVID pill paxlovid shows no benefit in younger adults, according to a study.